Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial - Université de Lorraine Access content directly
Journal Articles European Journal of Heart Failure Year : 2020

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

1 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
2 Charité Campus Virchow-Klinikum (CVK)
3 BCRT - Berlin-Brandenburg Center for Regenerative Medicine [Berlin, Germany]
4 DZHK - German Center for Cardiovascular Research
5 UMMC - University of Mississippi Medical Center
6 NKUA - National and Kapodistrian University of Athens
7 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
8 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
9 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
10 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
11 USP - Universidade de São Paulo = University of São Paulo
12 Saarland University [Saarbrücken]
13 UKS - Saarland University Hospital
14 MUMC - Maastricht University Medical Centre
15 SNUBH - Seoul National University Bundang Hospital
16 Max Superspeciality Hospital, Saket
17 Instituto Nacional de Cardiologia Ignacio Chavez
18 MUHC - McGill University Health Center [Montreal]
19 Fundacion Vallee del Lili
20 University Hospitals Leuven [Leuven]
21 Massachusetts General Hospital [Boston]
22 CHUS - Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne]
23 Semmelweis University of Medicine [Budapest]
24 Monash university
25 Department of Cardiology, FLENI Institute
26 Wayne State University [Detroit]
27 Wrocław Medical University
28 Hosp P Giovanni XXIII - Hospital Papa Giovanni XXIII
29 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
30 NHCS - National Heart Centre Singapore
31 Masaryk University Hospital
32 Glenfield Hospital
33 University of Pisa - Università di Pisa
34 Kyushu University
35 St. Michael's Hospital
36 University of Toronto
37 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
38 Fuwai Hospital Chinese Academic of Medical Science
39 Boehringer Ingelheim International GmbH
40 Boehringer Ingelheim Pharma GmbH & Co. KG
41 Universität Heidelberg [Heidelberg] = Heidelberg University
42 LSHTM - London School of Hygiene and Tropical Medicine
43 Baylor University Medical Center
44 Imperial College London
Iain Squire
  • Function : Author


Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
Fichier principal
Vignette du fichier
European J of Heart Fail - 2020 - Anker - Baseline characteristics of patients with heart failure with preserved ejection (1).pdf (328.18 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03758946 , version 1 (23-08-2022)


Attribution - NonCommercial



Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, et al.. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial. European Journal of Heart Failure, 2020, 22 (12), pp.2383-2392. ⟨10.1002/ejhf.2064⟩. ⟨hal-03758946⟩
21 View
39 Download



Gmail Facebook Twitter LinkedIn More